Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy Against Epithelial Tumors
Disclosures: Tae-Hwi Schwantes-An: Target RWE: Consultant, Eduardo Vilar-Gomez: Nothing to Disclose, Marco Abreu: Nothing to Disclose, Brent Neuschwander-Tetri: Akero: Consultant, Aligos: Consultant, Arrowhead: Consultant, Corcept: Consultant, GSK: Consultant, Hepion: Consultant, HIstoIndex: Consultant, Madrigal: Consultant, Madrigal: Grant/Research Support, Merck: Consultant, Mirum: Consultant, Sagimet: Consultant, Senseion: Consultant, HepGene: Stock privately held company, HeptaBio: Stock privately held company, Miriam Vos: Nothing to Disclose, Jian Wang: Nothing to Disclose, Xiuqing Guo: Nothing to Disclose, Jingyi Tan: Nothing to Disclose, Robert A Hegele: Nothing to Disclose, Nicholas Davidson: Nothing to Disclose, George Hindy: Regeneron Pharmaceuticals: Employee, Luca Lotta: Nothing to Disclose, Niek Verweij: Nothing to Disclose, Jerome Rotter: Nothing to Disclose, Naga Chalasani: Madrigal: Consultant, Zydus, Ipsen, Pfizer, Merck, Altimmune, GSK: Consultant, Exact Sciences: Grant/Research Support, NIH: Grant/Research Support 2567 EXPLORING THE PROTECTIVE ROLE OF LYPLAL1 LOSS-OF-FUNCTION IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE Rawdat Hussain 1 Chinmay Raut 1 Prabhu Ponnandy 1 Akram Irshaid 1 Brian Halligan 2 Elizabeth Speliotes 2 , 1 University of Michigan, 2 University of Michigan Medical Center Background: Human genetics studies have linked single-nucleotide polymorphisms near LYPLAL1 with metabolic dysfunction-associated steatotic liver disease (MASLD)
Perteghella et al., 2021), gastrodin (Yao et al., 2020
& Sharfi, A
